Amphetamines for Attention Deficit Hyperactivity Disorder (ADHD) in adults (Q24236404)

2

0 references

Rosa Bosch

object named as

Rosa Bosch

3

0 references

author name string

Xavier Castells

1

0 references

Mariana Nogueira

4

0 references

Miguel Casas

Cochrane Database of Systematic Reviews

5

0 references

publication date

15 June 2011

0 references

published in

0 references

cites work

Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

Long-acting stimulants for the treatment of attention-deficit disorder in cocaine-dependent adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

Pharmacotherapy of adult ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

Lisdexamfetamine in the treatment of attention-deficit/hyperactivity disorder in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

Stimulant treatment of adult attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

Stimulants: Therapeutic actions in ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

Scope and impact of financial conflicts of interest in biomedical research: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

Experimental investigations on dopamine transmission can provide clues on the mechanism of the therapeutic effect of amphetamine and methylphenidate in ADHD

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

Efficacy of Psychostimulant Drugs for Cocaine Dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

Amphetamine-induced place preference in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

A simple method for converting an odds ratio to effect size for use in meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

Meta-analyses involving cross-over trials: methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

Attention-deficit/hyperactivity disorder in adults: a survey of current practice in psychiatry and primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

New insights into the mechanism of action of amphetamines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

Age-dependent decline of attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

Drug preference and mood in humans: d-amphetamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

Inconclusive evidence puts Adderall back on the market

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

Wake-promoting agents with different mechanisms of action: comparison of effects of modafinil and amphetamine on food intake and cardiovascular activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

Behavioral and subjective effects of d-amphetamine and modafinil in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

Treatment strategies for co-occurring ADHD and substance use disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

The worldwide prevalence of ADHD: a systematic review and metaregression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

Neuropsychological performance in adult attention-deficit hyperactivity disorder: meta-analysis of empirical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

Substitution therapy for amphetamine users

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

Etiologic subtypes of attention-deficit/hyperactivity disorder: brain imaging, molecular genetic and environmental factors and the dopamine hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

Drug Therapy for Adults with Attention-Deficit Hyperactivity Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

Diagnosis and treatment of minimal brain dysfunction in adults: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

The adolescent outcome of hyperactive girls: self-report of psychosocial status

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

Efficacy of Adderall and methylphenidate in attention deficit hyperactivity disorder: a drug-placebo and drug-drug response curve analysis of a naturalistic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

Imputing response rates from means and standard deviations in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

Attention Deficit Hyperactivity Disorder: manifestation in adulthood

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

7 January 2021

Long-term safety and effectiveness of mixed amphetamine salts extended release in adults with ADHD.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

7 January 2021

Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

7 January 2021

Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

7 January 2021

A randomised, double-blind, placebo-controlled trial of dexamphetamine in adults with attention deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

7 January 2021

Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

7 January 2021

Subjective and behavioral effects of repeated d-amphetamine in humans

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

7 January 2021

12-month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

7 January 2021

Pharmacotherapy for obesity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

7 January 2021

Methylphenidate treatment for cocaine abusers with adult attention-deficit/hyperactivity disorder: a pilot study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

7 January 2021

A clinical perspective of attention-deficit/hyperactivity disorder into adulthood

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

7 January 2021

Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

7 January 2021

Functional impairments in adults with self-reports of diagnosed ADHD: A controlled study of 1001 adults in the community

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

7 January 2021

Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

7 January 2021

Triple-bead mixed amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD: a randomized, double-blind, multicenter, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

7 January 2021

Attention-deficit/hyperactivity disorder-specific quality of life with triple-bead mixed amphetamine salts (SPD465) in adults: results of a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007813.PUB2

7 January 2021